Corbus Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; Co. To Offer And Sell Common Stock Up To $127.50M Through Jefferies
-SEC Filing
Read original at benzingaStocks · News reference
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over losses of $(1.44) per
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 12:32 PM
- Checked
- Aug 6, 2026, 12:32 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
Read original at benzingaHC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.
Read original at benzinga